RGNX - Regenxbio Inc logo

Regenxbio Inc

RGNX

Regenxbio Inc. develops gene therapies using its NAV Technology Platform to deliver functional genes for genetic disorders. Its pipeline includes treatments for conditions like wet age-related macular degeneration and Duchenne muscular dystrophy.

โš•๏ธ Healthcare NASDAQ Listed 2015 $ USD
$1,000 invested 10 years ago โ†’$424today

Score Overview

1 Year
Score
Net Growth-1.32%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth2.37%
Rev TrendGrew
Revenue Consistencyโ€”
5 Years
Score3.3
Net Growth-253.65%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-62.90%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-211.96%
Net Trend50%
Net Income Consistency
Rev Growth38x
Rev Trend60%
Revenue Consistency
All Time
Score
Net Growth-6x
Net Trend45%
Net Income Consistency
Rev Growth22x
Rev Trend55%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Regenxbio Inc has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. RGNX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 7.17โ€”
1 Year2025-10-22
$ 12.19-41.18%
5 Years2021-10-22
$ 36.14-80.16%
10 Years2016-10-21
$ 16.90-57.57%
All Time2015-09-17
$ 30.45-76.45%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 174M-$ 196M$ 105M
2025$ 170M-$ 193M$ 230M
2024$ 83M-$ 227M$ 234M
2023$ 90M-$ 263M$ 275M
2022$ 112M-$ 280M$ 364M
2021$ 470M$ 127M$ 457M
2020$ 154M-$ 111M$ 475M
2019$ 35M-$ 94M$ 296M
2018$ 218M$ 99M$ 319M
2017$ 10M-$ 73M$ 160M
2016$ 4M-$ 62M$ 89M
IPO2015$ 7M-$ 22M$ 114M
RGNX - Regenxbio Inc logo

Regenxbio Inc fundamental performance

Between 2020 and 2025, revenue grew from $ 154M to $ 170M and net income went from -$ 111M to -$ 193M. Revenue increased in 2 of those 5 years; net income in 3.

Across Regenxbio Inc's full reported history, from 2015 to 2025, revenue grew from $ 7M to $ 170M and net income went from -$ 22M to -$ 193M. Revenue increased in 55% of the years measured; net income in 45%.

Regenxbio Inc currently holds a 5-year HDB Score of 3.3 out of 10. How the HDB Score is calculated.

Membership

Explore RGNX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies